[1]
|
Cottin, V., Hirani, N.A., Hotchkin, D.L., et al. (2018) Presentation, Diagnosis and Clinical Course of the Spectrum of Progressive-Fibrosing Interstitial Lung Diseases. European Respiratory Review, 27, Article ID: 180076.
https://doi.org/10.1183/16000617.0076-2018
|
[2]
|
Khanna, D., Mittoo, S., Aggarwal, R., et al. (2015) Connective Tissue Disease-Associated Interstitial Lung Diseases (CTD-ILD)—Report from OMERACT CTD-ILD Working Group. The Journal of Rheumatology, 42, 2168-2171.
https://doi.org/10.3899/jrheum.141182
|
[3]
|
Jeganathan, N. and Sathananthan, M. (2020) Connective Tissue Dis-ease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment. Lung, 198, 735-759. https://doi.org/10.1007/s00408-020-00383-w
|
[4]
|
Zhang, G., Xu, T., Zhang, H., et al. (2015) [Randomized Con-trol Multi-Center Clinical Study of Mycophenolate Mofetil and Cyclophosphamide in the Treatment of Connective Tissue Disease Related Interstitial Lung Disease]. Chinese Medical Journal, 95, 3641-3645.
|
[5]
|
Gutiérrez-Adrianzén, O.A., Koutouzov, S., Mota, R.M., Das Chagas Medeiros, M.M., Bach, J.F. and De Holanda Campos, H. (2006) Diagnostic Value of Anti-Nucleosome Antibodies in the Assessment of Disease Activity of Systemic Lupus Erythematosus: A Pro-spective Study Comparing Anti-Nucleosome with Anti-DsDNA Antibodies. The Journal of Rheumatology, 33, 1538-1544.
|
[6]
|
Ahmed, S. and Handa, R. (2022) Management of Connective Tissue Disease-Related Interstitial Lung Disease. Current Pulmonology Reports, 11, 86-98. https://doi.org/10.1007/s13665-022-00290-w
|
[7]
|
Yoo, H., Hino, T., Hwang, J., et al. (2022) Connective Tissue Disease-Related Interstitial Lung Disease (CTD-ILD) and Interstitial Lung Abnormality (ILA): Evolving Concept of CT Findings, Pathology and Management. European Journal of Radiol-ogy Open, 9, Article ID: 100419. https://doi.org/10.1016/j.ejro.2022.100419
|
[8]
|
Schulte, J.J. and Husain, A.N. (2020) Connective Tissue Disease Related Interstitial Lung Disease. Surgical Pathology Clinics, 13, 165-188. https://doi.org/10.1016/j.path.2019.11.005
|
[9]
|
Dale, R.C. (2016) Interleukin-6 Blockade as Rescue Therapy in Autoimmune Encephalitis. Neurotherapeutics, 13, 821-823. https://doi.org/10.1007/s13311-016-0471-1
|
[10]
|
Singh, J.A. (2016) Infections with Biologics in Rheumatoid Arthritis and Related Conditions: A Scoping Review of Serious or Hospitalized Infections in Observational Studies. Current Rheumatology Reports, 18, Article No. 61.
https://doi.org/10.1007/s11926-016-0609-5
|
[11]
|
Brito, Y., Glassberg, M.K. and Ascherman, D.P. (2017) Rheu-matoid Arthritis-Associated Interstitial Lung Disease: Current Concepts. Current Rheumatology Reports, 19, Article No. 79. https://doi.org/10.1007/s11926-017-0701-5
|
[12]
|
Raimundo, K., Solomon, J.J., Olson, A.L., et al. (2019) Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. The Journal of Rheumatology, 46, 360-369.
https://doi.org/10.3899/jrheum.171315
|
[13]
|
Spagnolo, P., Lee, J.S., Sverzellati, N., Rossi, G. and Cottin, V. (2018) The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis & Rheumatology, 70, 1544-1554. https://doi.org/10.1002/art.40574
|
[14]
|
Hyldgaard, C., Hilberg, O., Pedersen, A.B., et al. (2017) A Popula-tion-Based Cohort Study of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Comorbidity and Mortality. An-nals of the Rheumatic Diseases, 76, 1700-1706.
https://doi.org/10.1136/annrheumdis-2017-211138
|
[15]
|
Castelino, F.V. and Varga, J. (2010) Interstitial Lung Dis-ease in Connective Tissue Diseases: Evolving Concepts of Pathogenesis and Management. Arthritis Research & Therapy, 12, Article No. 213. https://doi.org/10.1186/ar3097
|
[16]
|
Carrasco Cubero, C., Chamizo Carmona, E. and Vela Casasempere, P. (2021) Systematic Review of the Impact of Drugs on Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis. Reumatología Clínica (English Edition), 17, 504-513. https://doi.org/10.1016/j.reumae.2020.04.010
|
[17]
|
Sparks, J.A., He, X., Huang, J., et al. (2019) Rheumatoid Ar-thritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study. Arthritis & Rheumatology, 71, 1472-1482. https://doi.org/10.1002/art.40904
|
[18]
|
Kelly, C.A., Saravanan, V., Nisar, M., et al. (2014) Rheumatoid Arthri-tis-Related Interstitial Lung Disease: Associations, Prognostic Factors and Physiological and Radiological Characteris-tics—A Large Multicentre UK Study. Rheumatology, 53, 1676-1682. https://doi.org/10.1093/rheumatology/keu165
|
[19]
|
Castellanos-Moreira, R., Rodríguez-García, S.C., Gomara, M.J., et al. (2020) Anti-Carbamylated Proteins Antibody Repertoire in Rheumatoid Arthritis: Evidence of a New Autoantibody Linked to Interstitial Lung Disease. Annals of the Rheumatic Diseases, 79, 587-594. https://doi.org/10.1136/annrheumdis-2019-216709
|
[20]
|
Juge, P.A., Lee, J.S., Ebstein, E., et al. (2018) MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. The New England Journal of Medicine, 379, 2209-2219. https://doi.org/10.1056/NEJMoa1801562
|
[21]
|
Kiely, P., Busby, A.D., Nikiphorou, E., et al. (2019) Is Incident Rheumatoid Arthritis Interstitial Lung Disease Associated with Methotrexate Treatment? Results from a Multi-variate Analysis in the ERAS and ERAN Inception Cohorts. BMJ Open, 9, e028466. https://doi.org/10.1136/bmjopen-2018-028466
|
[22]
|
Rojas-Serrano, J., Herrera-Bringas, D., Pérez-Román, D.I., Pérez-Dorame, R., Mateos-Toledo, H. and Mejía, M. (2017) Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Severity of Lung Disease Are Associated to Prognosis. Clinical Rheumatology, 36, 1493-1500. https://doi.org/10.1007/s10067-017-3707-5
|
[23]
|
Vicente-Rabaneda, E.F., Atienza-Mateo, B., Blanco, R., et al. (2021) Efficacy and Safety of Abatacept in Interstitial Lung Disease of Rheumatoid Arthritis: A Systematic Lit-erature Review. Autoimmunity Reviews, 20, Article ID: 102830.
https://doi.org/10.1016/j.autrev.2021.102830
|
[24]
|
Md Yusof, M.Y., Kabia, A., Darby, M., et al. (2017) Effect of Rituximab on the Progression of Rheumatoid Arthritis-Related Interstitial Lung Disease: 10 Years’ Experience at a Single Centre. Rheumatology, 56, 1348-1357.
https://doi.org/10.1093/rheumatology/kex072
|
[25]
|
Huang, Y., Lin, W., Chen, Z., Wang, Y., Huang, Y. and Tu, S. (2019) Effect of Tumor Necrosis Factor Inhibitors on Interstitial Lung Disease in Rheumatoid Arthritis: Angel or Demon. Drug Design, Development and Therapy, 13, 2111-2125.
https://doi.org/10.2147/DDDT.S204730
|
[26]
|
Gan, D., Cheng, W., Ke, L., et al. (2021) Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis. Frontiers in Pharmacology, 12, Article 631891. https://doi.org/10.3389/fphar.2021.631891
|
[27]
|
Manfredi, A., Sebastiani, M., Cassone, G., Colaci, M., Sandri, G. and Ferri, C. (2018) Tocilizumab for the Treatment of Patients with Rheumatoid Arthritis and Interstitial Lung Diseases: A Case Series. Clinical and Experimental Rheumatology, 36, 342.
|
[28]
|
Naotatsu Otsuji, K.S., Hajime Arifuku, K.N., Hiroyoshi Watanabe, T.W., Kenya Koyama, H.H. and Fukushima, Y. (2020) Effect of Tocilizumab on Interstitial Lung Disease (ILD) in Patients with Rheumatoid Arthritis (RA). European Respiratory Journal, 56, 747. https://doi.org/10.1183/13993003.congress-2020.747
|
[29]
|
Manfredi, A., Cassone, G., Furini, F., et al. (2020) To-cilizumab Therapy in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicentre Retrospective Study. Internal Medicine Journal, 50, 1085-1090.
https://doi.org/10.1111/imj.14670
|
[30]
|
杨书琦, 张慧芳, 宋书林, 余旻. 系统性硬化症发病机制的研究进展[J]. 医学综述, 2018, 24(1): 17-21.
|
[31]
|
Sánchez-Cano, D., Ortego-Centeno, N., Callejas, J.L., et al. (2018) Interstitial Lung Disease in Systemic Sclerosis: Data from the Spanish Scleroderma Study Group. Rheumatology International, 38, 363-374.
https://doi.org/10.1007/s00296-017-3916-x
|
[32]
|
Steele, R., Hudson, M., Lo, E. and Baron, M. (2012) Clinical De-cision Rule to Predict the Presence of Interstitial Lung Disease in Systemic Sclerosis. Arthritis Care & Research, 64, 519-524. https://doi.org/10.1002/acr.21583
|
[33]
|
Bergamasco, A., Hartmann, N., Wallace, L. and Verpillat, P. (2019) Epidemiology of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease. Clinical Epidemiology, 11, 257-273.
https://doi.org/10.2147/CLEP.S191418
|
[34]
|
Elhai, M., Meune, C., Boubaya, M., et al. (2017) Mapping and Pre-dicting Mortality from Systemic Sclerosis. Annals of the Rheumatic Diseases, 76, 1897-1905. https://doi.org/10.1136/annrheumdis-2017-211448
|
[35]
|
Ashmore, P., Tikly, M., Wong, M. and Ickinger, C. (2018) Interstitial Lung Disease in South Africans with Systemic Sclerosis. Rheumatology International, 38, 657-662. https://doi.org/10.1007/s00296-017-3893-0
|
[36]
|
Wangkaew, S., Euathrongchit, J., Wattanawittawas, P., Kasitanon, N. and Louthrenoo, W. (2016) Incidence and Predictors of Interstitial Lung Disease (ILD) in Thai Patients with Early Systemic Sclerosis: Inception Cohort Study. Modern Rheumatology, 26, 588-593. https://doi.org/10.3109/14397595.2015.1115455
|
[37]
|
Winstone, T.A., Assayag, D., Wilcox, P.G., et al. (2014) Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease: A Systematic Review. Chest, 146, 422-436. https://doi.org/10.1378/chest.13-2626
|
[38]
|
Wu, W., Jordan, S., Becker, M.O., et al. (2018) Prediction of Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis: The SPAR Model. Annals of the Rheumatic Diseases, 77, 1326-1332.
https://doi.org/10.1136/annrheumdis-2018-213201
|
[39]
|
Scott, L.J. (2017) Tocilizumab: A Review in Rheumatoid Arthritis. Drugs, 77, 1865-1879.
https://doi.org/10.1007/s40265-017-0829-7
|
[40]
|
Mihai, C., Dobrota, R., Schröder, M., et al. (2020) COVID-19 in a Patient with Systemic Sclerosis Treated with Tocilizumab for SSc-ILD. Annals of the Rheumatic Diseases, 79, 668-669.
https://doi.org/10.1136/annrheumdis-2020-217442
|
[41]
|
Khanna, D., Lin, C., Furst, D.E., et al. (2022) Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 205, 674-684. https://doi.org/10.1164/rccm.202103-0714OC
|
[42]
|
Kudsi, M., Khalayli, N., Tarcha, R. and Al-Darwish, L. (2023) Tocilizumab in Systemic Sclerosis Treatment: A Case Report. Annals of Medicine & Surgery, 85, 4586-4588. https://doi.org/10.1097/MS9.0000000000000969
|
[43]
|
Flores-Chávez, A., Kostov, B., Solans, R., et al. (2018) Se-vere, Life-Threatening Phenotype of Primary Sjögren’s Syndrome: Clinical Characterisation and Outcomes in 1580 Pa-tients (GEAS-SS Registry). Clinical and Experimental Rheumatology, 112, 121-129.
|
[44]
|
Ghosh, A., Das, T., Ghosh, A., Karmakar, P. and Pal, J. (2012) Evaluation of Respiratory Manifestations in Systemic Lupus Erythematosus with Special Reference to Pulmonary Interstitial Involvement. Journal of Indian Medical Association, 110, 109-111.
|
[45]
|
Zacay, G. and Levy, Y. (2018) Outcomes of Patients with Systemic Sclerosis Treated with Tocilizumab: Case Series and Review of the Literature. Best Practice & Research Clinical Rheumatology, 32, 563-571.
https://doi.org/10.1016/j.berh.2019.01.011
|
[46]
|
Ma, C.Y., Bikash, S., Li, H., Ding, Q.J. and Fu, P. (2022) Tocili-zumab Therapy for Persistent High-Grade Fever in Systemic Lupus Erythematosus: Two Cases and a Literature Review. Journal of International Medical Research, 50, 1-17. https://doi.org/10.1177/03000605221088558
|
[47]
|
陈建锋, 李庆华, 彭建军. 托珠单抗治疗难治性全身型幼年特发性关节炎疗效及安全性[J]. 儿科药学杂志, 2021, 27(11): 8-11.
|